Where Is Botox Injected for TMJ?

Botox for TMJ disorders is most commonly injected into the masseter muscle, the powerful jaw-clenching muscle you can feel tighten at the angle of your jaw. Depending on your specific symptoms, injections may also go into the temporalis muscle along the side of your head and, less commonly, the lateral pterygoid muscle deeper in the jaw. The exact sites, number of injection points, and doses vary because there are no standardized protocols for this use, and the treatment remains off-label in the United States.

The Masseter Is the Primary Target

The masseter is the workhorse of jaw clenching and grinding, and it is by far the most frequently injected muscle for TMJ-related pain and bruxism. It sits along the outside of the jaw, running from the cheekbone down to the angle of the mandible. You can locate it yourself by placing your fingers on your lower cheek and biting down hard; the muscle that bulges is the masseter.

A typical treatment involves multiple injection points spread across the lower portion of the muscle. Most practitioners use three sites within the masseter on each side, though the exact layout depends on your anatomy and symptom pattern. A recent review mapped designated injection points within the masseter to optimize localized relief, with separate points targeting different regions of the muscle belly.¹ The goal is to weaken the muscle enough to reduce excessive clenching force without eliminating your ability to chew normally.

Not all parts of the masseter are equally safe to inject. A cadaveric study mapped the facial nerve, parotid gland, parotid duct, and major blood vessels in the masseter region and identified a triangular safe zone in the lower portion of the muscle where the probability of hitting these structures is relatively low.² Injecting too high or too far back risks affecting the parotid gland or branches of the facial nerve, which could temporarily impair your smile.

The Temporalis and Lateral Pterygoid

The temporalis is the fan-shaped muscle along the side of your skull, above and in front of your ear. If you press your fingertips to your temple while clenching, you will feel it engage. When TMJ pain involves headaches or tenderness radiating up the side of the head, the anterior fibers of the temporalis are sometimes included in the treatment plan. Injection points for the temporalis generally sit along the front portion of the muscle, where the fibers are most active during jaw closing.

The lateral pterygoid is a different story entirely. This small muscle sits deep inside the jaw, behind the cheekbone, and plays a role in opening the mouth and moving the jaw forward and side to side. It is implicated in painful jaw clicking and disc displacement. Because of its depth, reaching it with a needle is considerably harder than reaching the masseter or temporalis.

There are two approaches to the lateral pterygoid. The extraoral method involves inserting the needle through the skin near the coronoid notch, angling it roughly 45 degrees, about a centimeter below the center of the cheekbone and slightly in front of the jaw condyle.³ The intraoral method inserts the needle through the mouth, going in behind the upper back teeth at a 45-degree angle.⁴ Both routes require careful technique because the muscle is surrounded by the pterygoid venous plexus, and an accidental intravascular injection would be a problem.

How Practitioners Find the Right Spot

Masseter injections are frequently done “blind,” meaning the practitioner relies on external landmarks and palpation to place the needle. For a muscle as superficial and easy to feel as the masseter, this works reasonably well, but there is growing interest in using ultrasound guidance. A review of ultrasound-guided techniques found that imaging improves the precision of injections compared to conventional blind methods, particularly for identifying the muscle’s boundaries and avoiding nearby structures.⁵

For the lateral pterygoid, guidance becomes more important. Because of the muscle’s depth and the surrounding vascular network, electromyography (EMG) has traditionally been used to confirm needle placement. EMG picks up the electrical activity of the muscle in real time, so the practitioner knows the needle tip is actually in the lateral pterygoid and not in adjacent tissue.⁴ In practice, though, many clinicians who inject the lateral pterygoid use anatomical landmarks alone, and the added cost and setup of EMG mean it is not universal.

There is also an emerging concept of targeting motor endplate zones within the masseter, the specific bands where nerve endings connect to muscle fibers. Anatomical and electrophysiological studies suggest these zones are concentrated in restricted areas, and delivering Botox close to them could allow more efficient muscle weakening with lower doses. That said, direct clinical evidence showing this approach is better than conventional placement is still insufficient.⁶

What the Evidence Actually Shows About Effectiveness

If you have read this far expecting a clear endorsement, the research picture is more complicated than you might hope. An uncontrolled pilot study found encouraging numbers: about 85% of patients saw improvement in pain during mouth opening, 90% improved during chewing, and 70% experienced fewer headaches.⁷ Those numbers look impressive, but “uncontrolled” is the key word. Without a placebo comparison, it is impossible to know how much of the improvement came from the injection itself versus the natural course of the disorder or placebo effect.

When researchers did use placebo controls and pooled data across multiple trials, the picture dimmed. A systematic review and meta-analysis found that Botox was not significantly better than placebo for reducing pain scores at one, three, or six months. There was also no meaningful difference for maximum mouth opening, bruxism events, or bite force.⁸ A broader review concluded that while there is good evidence supporting Botox for masseter hypertrophy specifically, the evidence for muscle-related TMJ pain is equivocal, and there is very little support for joint-related TMJ disorders.⁹

This does not mean it never works for anyone. Many patients and clinicians report real improvements, and the timing of assessment seems to matter. Patients reported less improvement if their follow-up was earlier than about five weeks after injection, compared to those assessed at five to ten weeks, suggesting the full effect takes time to develop.¹⁰ The mismatch between individual reports and controlled trial data is a genuine puzzle in this field, and it is one reason protocols remain unstandardized.

How Botox for TMJ Compares to Splint Therapy

Occlusal splints, the custom-fitted mouthguards worn during sleep, are probably the most common conservative treatment for bruxism-related TMJ problems. Several trials have compared them head-to-head with Botox, and the results depend on what you measure and when.

One trial found that in the first one to three months, Botox patients had better jaw mobility and lower pain scores than the splint group, suggesting faster early relief. By six months, though, the two groups had converged, with no significant difference between them.¹¹ Another trial found that both approaches reduced pain similarly over six months, but Botox actually performed worse on jaw function measures like pain-free opening, maximum opening, and protrusion.¹²

Interestingly, one study of patients with implant-supported dentures found that combining Botox with a splint led to significantly better satisfaction and sleep quality than either treatment alone, sustained over a full year.¹³ The combination approach makes intuitive sense: the splint protects teeth and redistributes bite forces overnight, while Botox dials down the overall clenching intensity. If your practitioner suggests trying both, that is not unusual.

Side Effects and What to Watch For

A large dataset of over 2,000 masseter Botox sessions tracked complication rates in detail. The most common side effect was a temporary decrease in chewing force, reported after about 30% of sessions. Bruising occurred in roughly 2.5% of treatments. Less common complications included headaches after about 0.6% of sessions, paradoxical muscle bulging in about 0.5%, sunken cheeks from volume loss below the cheekbone in about 0.4%, and smile limitation in about 0.15%.¹⁴

The chewing weakness is expected and usually mild; it is essentially the intended effect overshooting a little. Smile limitation happens when the toxin migrates to the nearby risorius or zygomaticus muscles, which help pull the corners of the mouth upward. This is temporary and resolves as the Botox wears off, but it is understandably distressing when it happens. The paradoxical bulging occurs when weakening the superficial masseter fibers causes the deeper fibers to become more visible on clenching, creating a bump rather than the expected slimming. Sunken cheeks from subzygomatic volume loss tend to concern patients who receive repeated treatments for cosmetic jawline slimming, though the same phenomenon can affect TMJ patients over time.

The Bone Loss Question

This is where the conversation gets more serious, and it is a concern many patients are not told about. When Botox weakens the masseter, the reduced mechanical loading on the jawbone appears to trigger bone density changes. Animal studies in rabbits showed that Botox-induced masseter paralysis caused notable and persistent bone loss, particularly at the temporomandibular joint itself.¹⁵

A systematic review of the available literature, including animal and human studies, confirmed that Botox-induced masticatory muscle atrophy promotes mandibular bone loss. The most frequently affected areas were the condylar head, coronoid process, and ramus, and common changes included decreased bone volume, reduced cortical thickness, and lower cortical and trabecular density.¹⁶ A broader review compiling evidence from mice, rats, rabbits, and human studies reached the same conclusion.¹⁷

The effect appears to be worse for some populations than others. A study in women found that the quality of cortical bone at muscle insertion sites decreased after Botox injections, and these effects were significantly greater in postmenopausal women compared to younger women.¹⁸ If you are postmenopausal or have other risk factors for bone loss, this is worth discussing with your provider before committing to repeated injection cycles.

The clinical significance is still being debated. Bone density changes visible on a CT scan do not necessarily mean your jaw will fracture or your joint will deteriorate. But for someone receiving masseter Botox every three to four months over years, the cumulative effect is a real unknown. This is one reason some researchers argue these injections should be reserved for cases that have not responded to more conservative treatments.

Off-Label Status and the Lack of a Standard Protocol

Botox is FDA-approved for several conditions, including chronic migraine, cervical dystonia, and overactive bladder, but TMJ disorders are not on the list. Every TMJ injection is off-label, meaning practitioners are using the drug based on clinical judgment and the available literature rather than a formally reviewed and approved indication.¹⁹ Off-label use is legal and common in medicine, but it means insurance coverage is inconsistent, and you may end up paying out of pocket.

The lack of standardized injection protocols is a practical headache. Doses reported in the literature for the masseter alone range widely, and the number of injection points, the depth of the needle, and the decision about whether to include the temporalis or lateral pterygoid all vary from provider to provider. One clinician may inject 25 units of onabotulinumtoxinA per side into three masseter points; another may use 50 units per side across five points. Different brands of botulinum toxin (Dysport, Xeomin) have different unit potencies, adding another layer of confusion if you switch providers.

The practical takeaway: ask your provider which muscles they plan to inject, how many units they will use, and why they chose that protocol. A provider who can explain their reasoning and adjust based on your response is more important than finding the “right” number from a paper.

When Botox Makes Less Sense for TMJ

TMJ disorders are not a single condition. The broad category includes muscle-related problems like myofascial pain and bruxism, joint-related problems like disc displacement and arthritis, and combinations of both. The evidence, such as it is, best supports Botox for muscle-dominant problems, particularly masseter hypertrophy and clenching-related pain. For joint-related clicking, locking, or degenerative changes within the joint capsule itself, the data is thin.⁹

A randomized trial did show benefit from injecting the lateral pterygoid in patients with painful clicking, suggesting some joint-related symptoms can respond when a specific muscle is driving the problem.³ But as a general rule, if your TMJ issues are primarily structural, like a displaced disc, or degenerative, Botox addresses the muscular component at best. It does not fix the joint mechanics.

One randomized trial comparing two dosing protocols for bruxism found that both reduced pain over 180 days, but also caused a measurable decrease in posterior bite force that lasted through the four-month mark before recovering.²⁰ For most people, this temporary reduction in bite force is manageable. But if your jaw is already weak or you have difficulty eating, weakening the muscles further could make daily life harder rather than easier. Patients who are pregnant, breastfeeding, or have neuromuscular diseases like myasthenia gravis are generally excluded from treatment as well.

What Happens During the Appointment

The actual injection visit is quick, usually fifteen to thirty minutes. You will be asked to clench your jaw so the practitioner can palpate and mark the masseter and, if relevant, the temporalis. The skin is cleaned, and some providers apply a topical numbing cream, though many skip it because the needles used are fine enough that the discomfort is brief. You will feel a series of small pricks as the toxin is deposited at each marked point. For the lateral pterygoid, the process is more involved and may use a longer needle with imaging or EMG guidance.

Results are not immediate. Botox takes several days to begin blocking nerve signals at the muscle, and the full effect on jaw tension typically develops over two to six weeks. As noted earlier, patients assessed before the five-week mark tended to report less benefit than those evaluated later.¹⁰ If your first round does not seem to help, your provider may adjust the dose or injection sites before writing off the treatment entirely. Effects typically last three to four months before the muscle activity gradually returns, and repeat injections are scheduled on that cycle if the initial treatment worked.